# Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)

> **NCT02132754** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 116 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** MK-4166
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02132754
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-27
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-07-31
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132754, "Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02132754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*